Skip to content
OTC Biotech
  • Home
  • Contact
  • About
    • Privacy Policy

Jaguar Health to Forge Ahead with Efforts to Fight Rare and Orphan Diseases in the U.S. and Europe

January 27, 2023 by Allen Williams

Jaguar Health, Inc. is taking a bold step forward in its mission to make a difference in the rare and orphan disease space. Through its … Read more

Biologics Take Giant Leap Forward: Biotech Firm Prepares for NB1 Pilot Clinical Trial with Help from Expert Contract Research Organization

January 27, 2023 by Allen Williams

Bone Biologics Corporation, a leader in developing orthobiologic products for spine fusion markets, is thrilled to announce their collaboration with Avania, a renowned global, full-service … Read more

Study Reveals Successful Transfection of T-cells Using Kytopen’s Flowfect® Technology

January 27, 2023 by Allen Williams

BioCentriq, Inc., a New Jersey-based CDMO for cell and gene therapies, has just concluded a study to evaluate the viability, transfection efficiency, and post-transfection growth … Read more

Nogra Pharma and Torii Pharmaceutical Forge Groundbreaking Deal to Bring Revolutionary Acne Treatment to Japan

January 27, 2023 by Allen Williams

Nogra Pharma, a biotechnology company dedicated to creating groundbreaking therapies for immune-inflammatory-mediated diseases, has just announced a major licensing agreement with Torii Pharmaceutical Co., Ltd. … Read more

Panbela Set to Unleash $15 Million in Public Offerings!

January 27, 2023 by Allen Williams

Panbela Therapeutics Inc., a clinical stage company developing groundbreaking therapeutics for the treatment of patients with urgent unmet medical needs, has announced the pricing of … Read more

Unlock Your Brain Power: 10 In-Demand Neuroscience Jobs You Can’t Afford to Miss!

January 27, 2023 by Allen Williams

The COVID-19 pandemic has sparked an increased demand for biopharma candidates, with the neuroscience field experiencing a particularly noticeable surge. As this sector continues to … Read more

New Study Warns of Increased Risk of Rare VEXAS Syndrome

January 27, 2023 by Allen Williams

A startling revelation was made on Tuesday – a previously unknown syndrome with a high mortality rate is far more common than previously thought. The … Read more

Ocuphire Pushes Ahead with Promising Diabetic Retinopathy Drug Despite Missing Primary Goal

January 27, 2023 by Allen Williams

Ocuphire Pharma is forging ahead with an FDA end-of-Phase II meeting, despite not achieving the primary endpoint with its oral diabetic retinopathy (DR) drug, APX3330. … Read more

AML Trial Halted Following Patient Death

January 27, 2023 by Allen Williams

Magenta Therapeutics has placed an immediate pause on the Phase I/II dose-escalation trial of its AML therapy following the unfortunate death of a patient. The … Read more

Breakthrough Vaccine Candidate Could Revolutionize Treatment of Down Syndrome

January 27, 2023 by Allen Williams

AC Immune’s anti-amyloid-beta vaccine candidate ACI-24.060 has, according to interim data from the Phase Ib/II ABATE trial, been found to be safe and effective in … Read more

Enlivex Unlocks Promising New Treatment Option for Advanced Solid Tumors with Positive DSMB Recommendation

January 26, 2023 by Allen Williams

Enlivex Therapeutics Ltd. has made a significant breakthrough in their pioneering macrophage reprogramming immunotherapy clinical trial, as an independent Data and Safety Monitoring Board has … Read more

Revolutionary Treatments for Early-Stage Dupuytren’s Disease: A Review

January 26, 2023 by Allen Williams

Today, a review providing evidence-based treatments for early stage Dupuytren’s disease has been published in The Journal of Hand Surgery (European Volume) by 180 Life … Read more

Unlocking the Key to Parkinson’s Treatment: Inhibikase Therapeutics Reveals c-Abl as a Promising Target

January 26, 2023 by Allen Williams

Inhibikase Therapeutics, Inc. has made a breakthrough in the battle against Parkinson’s and related disorders. The company recently published a study in Science Translational Medicine … Read more

Phio Pharmaceuticals Reverses Course – Announces January 25, 2023 Stock Split!

January 26, 2023 by Allen Williams

Phio Pharmaceuticals Corp., a clinical stage biotechnology company, is taking a bold step forward with its INTASYL™ RNAi platform technology. On January 26, 2023, the … Read more

Jasper Therapeutics Raises $90 Million in Historic Public Offering of Common Stock

January 26, 2023 by Allen Williams

Jasper Therapeutics, Inc., a biotechnology company that is revolutionizing the field of medicine with its novel antibody therapies, has announced the pricing of an underwritten … Read more

Acasti Reclaims Compliance with NASDAQ: Extends Time to Meet Minimum Bid Price Requirement

January 26, 2023 by Allen Williams

Acasti Pharma Inc., a late-stage specialty pharma company developing treatments for rare and orphan diseases, has been granted a 180-day extension by the NASDAQ Listing … Read more

Psychedelic-Derived Obesity Treatment: Professor Joseph Tam Brings Hope for Future Weight Loss at Isranalytica 2023

January 26, 2023 by Allen Williams

Clearmind Medicine Inc., a pioneering biotech company devoted to uncovering and developing novel psychedelic-derived therapeutics, proudly announced today that Professor Joseph Tam, D.M.D., Ph.D., presented … Read more

Psychedelic Therapy Shows Promising Results in Treating Depression in Clinical Trial

January 26, 2023 by Allen Williams

On Wednesday, Small Pharma made a major breakthrough in the development of treatment for major depressive disorder (MDD) when they reported positive results from their … Read more

Tech Revolution: VC Fund Reaps Massive $350M Windfall as Tech Giants Falter

January 26, 2023 by Allen Williams

On Wednesday, three venture capitalists unveiled an exciting new endeavor: Dimension I, a $350 million fund to revolutionize the biotech industry. With this bold move, … Read more

Merck’s Keytruda: A Tale of Triumph and Disappointment

January 26, 2023 by Allen Williams

Wednesday was an eventful day for Merck’s blockbuster drug Keytruda (pembrolizumab), as it suffered a rare setback in prostate cancer while simultaneously celebrating a major … Read more

T. Denny Sanford Makes Historic Donation to Sanford Burnham Prebys, Aiming to Attract the Best in Biomedical Research

January 25, 2023 by Allen Williams

Sanford Burnham Prebys is proud to announce a major recruitment drive, with up to 20 new faculty positions set to be filled in the fields … Read more

Unlock the Secrets of Biopharma Innovation: Cerevance to Join SVB Global Conference

January 25, 2023 by Allen Williams

Cerevance, a groundbreaking clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, is proud to announce that Craig Thompson, the company’s … Read more

Dyadic Begins Human Testing of its Recombinant Protein RBD Booster Vaccine Candidate to Combat COVID-19

January 25, 2023 by Allen Williams

Dyadic International, Inc., a pioneering biotechnology company, has made a major breakthrough in the fight against COVID-19. The company has initiated dosing in its Phase … Read more

Robert Eno Joins HeartBeam as President, Bringing Decades of Leadership Experience to the Table

January 25, 2023 by Allen Williams

HeartBeam Inc. (NASDAQ: BEAT), a groundbreaking cardiac technology company, is delighted to welcome Robert Eno to their executive team in the newly created position of … Read more

Medical Device Expert Michael Nketiah Joins Nexalin Technology as Senior VP of Quality, Clinical and Regulatory

January 25, 2023 by Allen Williams

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) is thrilled to welcome Michael Nketiah to its leadership team as Senior Vice President of Quality, Clinical and Regulatory. … Read more

New Real-World Study Reveals Risks of Accidental Dosing Errors with Twice-Nightly Oxybates

January 25, 2023 by Allen Williams

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on improving treatments to improve lives, recently unveiled real-world data showing the risk of accidental dosing errors with … Read more

Revealing Study Uncovers Unknown Illness Affecting Thousands

January 25, 2023 by Allen Williams

The discovery of the genetic basis of VEXAS syndrome in 2020 was a major breakthrough in medical research. But how many people in the United … Read more

A New Hope for Long COVID Sufferers: Axcella Clears Regulatory Hurdles

January 25, 2023 by Allen Williams

Axcella Therapeutics is making strides in the fight against Long COVID fatigue with its AXA1125 therapeutic. On Monday, the U.K.’s Medicines and Healthcare products Regulatory … Read more

Biogen-Ionis Adcomm to Put Promising ALS Biomarker to the Test

January 25, 2023 by Allen Williams

On March 22nd, Biogen and Ionis’ experimental therapy for superoxide dismutase 1 (SOD1) ALS, Tofersen, will have its fate in the hands of the FDA’s … Read more

Pliant Reveals Impressive IPF Data, Seeks $175 Increase in Investment

January 25, 2023 by Allen Williams

Monday marked a major milestone for Pliant Therapeutics, as the company launched its public offering of $175 million worth of common stock. These funds will … Read more

Unlock the Potential of Your Specimen – Join Sequire Biotechnology at Their Conference on February 2, 2023!

January 23, 2023 by Allen Williams

Tracy Curley, CEO of iSpecimen Inc. (Nasdaq: ISPC), is excited to be part of the Sequire Biotechnology Conference on Thursday, February 2, 2023. As an … Read more

Hemogenyx Pharmaceuticals PLC: HEMO-CAR-T Successfully Passes Third Process Qualification Run!

January 23, 2023 by Allen Williams

Hemogenyx Pharmaceuticals plc is delighted to announce the successful completion of its third Process Qualification run of the end-to-end manufacturing process for its HEMO-CAR-T cells. … Read more

IntelGenx and Arwan Strike Deal to Bring RIZAPORT® to Middle East and North Africa!

January 23, 2023 by Allen Williams

Today, IntelGenx Corp, a leader in pharmaceutical films, has entered into an exclusive supply agreement with ARWAN Pharmaceuticals Industries Lebanon s.a.l. for their revolutionary product, … Read more

Alvotech Secures $137 Million Investment in Private Share Placement

January 23, 2023 by Allen Williams

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, is pleased to announce the completion of a … Read more

MannKind’s Revolutionary Inhaled Clofazimine Set to Tackle Rare Lung Disease in Adaptive Phase 2/3 Clinical Study

January 23, 2023 by Allen Williams

MannKind Corporation, a leader in the development and commercialization of inhaled therapeutic products to treat endocrine and orphan lung diseases, today announced the launch of … Read more

Revolutionary Machine Vision Technology from Asensus Surgical Now Approved for European Markets!

January 23, 2023 by Allen Williams

Asensus Surgical Inc. has made a thrilling leap forward in medical technology with the CE Mark approval of expanded machine vision capabilities on the previously-cleared … Read more

AstraZeneca Launches Hostile Takeover of CinCor Pharma, Inc. – Can CinCor Fend off the Acquisition?

January 23, 2023 by Allen Williams

Today, AstraZeneca, through a subsidiary, begins a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor) for a combined $36 per share … Read more

European Patent Office Scraps Regenlab’s PRP Patents – Breaking News from Estar Medical

January 23, 2023 by Allen Williams

Estar Medical® has had a string of successes this month in its efforts to invalidate Regenlab’s original patent for platelet rich plasma (PRP) at the … Read more

Revolutionary Cell Therapy Doses First US Leukemia Patient with Smart Immune’s SMART101 Treatment

January 23, 2023 by Allen Williams

Today, Smart Immune SAS, a clinical-stage biotechnology company, made an exciting announcement: the first adult leukemia patient has been successfully dosed with SMART101, a revolutionary … Read more

Helius Medical Technologies, Inc. Sees Record-Breaking Results for Fourth Quarter and Full Year 2022

January 23, 2023 by Allen Williams

Helius Medical Technologies, Inc., a neurotech company with a mission to promote neurological wellness, is pleased to announce preliminary, unaudited results for the quarter and … Read more

Discovering What’s Next: Join TCT BioPharm for a Shareholder Update Call!

January 20, 2023 by Allen Williams

On Monday, February 20th, 2023, TC BioPharm (Holdings) PLC, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, will be … Read more

Experience Explosive Growth with Catent, Inc.: Second Quarter FY 2023 Earnings Conference Webcast

January 20, 2023 by Allen Williams

Catalent, Inc. (NYSE: CTLT) – the global leader in developing, launching and supplying better treatments for patients – will be releasing its financial results for … Read more

Unlock Your Business Potential: Join Us for the Nu.Q® Vet Commercial Strategy Webinar!

January 20, 2023 by Allen Williams

Join VolitionRX Limited (NYSE AMERICAN: VNRX) for an exciting webinar hosted by Edison Group! During the event, Volition’s multi-national epigenetics company will be discussing their … Read more

Jazz Pharmaceuticals Sees $375M Payoff with Zymeworks Investment in GI Cancer Treatment

January 20, 2023 by Allen Williams

Jazz Pharmaceuticals’ $375 million investment into Zymeworks appears to be a smart move, as the two companies announced “impressive” results on Thursday from a Phase … Read more

Uncovering the Secrets of Biotech IP: Ryan Davies Interviews a Leading Expert

January 20, 2023 by Allen Williams

CancerVAX, Inc., a pre-clinical biotechnology company on a mission to develop powerful immunotherapy cancer treatments, is proud to announce that CEO Ryan Davies recently shared … Read more

Dr. Reddy’s Takes Giant Leap Forward With Completion of Clinical Studies for U.S. and European Submission of Rituximab Biosimilar

January 20, 2023 by Allen Williams

Dr. Reddy’s Laboratories Ltd., a world-leading pharmaceutical company, has achieved a major milestone with the successful completion of all clinical trials for its proposed rituximab … Read more

Aptorum Group Executes Dramatic Reverse Stock Split, Ratio of 1-for-10

January 20, 2023 by Allen Williams

At SK bioscience, we are dedicated to promoting global health and wellbeing from prevention to cure. Through our cutting-edge vaccine development technologies, we are standing … Read more

BIOSCIENCE GIANT Appoints New Executives to Drive Ahead with Ambitious Growth Plans

January 20, 2023 by Allen Williams

SK bioscience, a global leader in innovative vaccine and biotech solutions that prioritize human health, has welcomed Richard Kensinger, PhD, to the team as Vice … Read more

Deciphera Pharmaceuticals Launches Public Offering of Common Stock – Invest Now!

January 20, 2023 by Allen Williams

Deciphera Pharmaceuticals, a biopharmaceutical company dedicated to discovering and developing innovative medicines to improve the lives of cancer patients, has announced the pricing of a … Read more

Unlock the Possibility of a Cure for Acute Myeloid Leukemia: BriSTAR Immunotech to Present its Revolutionary Cell Therapy at AACR Special Conference on AML and MDS

January 20, 2023 by Allen Williams

At the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023 in Austin, TX, … Read more

Angle PLC Strengthens Leadership with Appointment of Non-Executive Director

January 19, 2023 by Allen Williams

ANGLE plc, a revolutionary liquid biopsy company, is pleased to welcome Dr. Joseph (Joe) Eid to its board of Non-Executive Directors. Dr. Eid’s appointment will … Read more

Unlocking the Potential of Cell-Specific Promoters: Annogen and VectorY Join Forces in a Groundbreaking Research Collaboration

January 19, 2023 by Allen Williams

Annogen is working to create multiple CNS-cell specific promoters that can be used in VectorY programs. This innovative approach will help to further advance the … Read more

Prenetics Brings Onboard Leading Geneticist Dr. Bayju Thakar as Chief Executive Officer of EMEA

January 19, 2023 by Allen Williams

Prenetics Global Limited, a leader in the fields of genomic and diagnostic testing, is proud to announce the appointment of Dr. Bayju Thakar as CEO … Read more

Scenic Biotech Bolsters Drug Discovery Capabilities with the Appointment of Kristof Van Emelen

January 19, 2023 by Allen Williams

Scenic Biotech, a leader in the groundbreaking world of genetic modifier drugs, has announced the appointment of Kristof Van Emelen, PhD, as Vice President of … Read more

Dr. Peter Hovstadius Joins XNK Therapeutics as Chief Medical Officer

January 19, 2023 by Allen Williams

XNK Therapeutics AB has appointed Dr. Peter Hovstadius as its new Chief Medical Officer, effective immediately. He will join the company’s management team, while Dr. … Read more

NRx Pharmaceuticals Announces Major Progress in Path to NDA Submission for Promising New Treatment: NRX-101

January 19, 2023 by Allen Williams

Last week, NRx Pharmaceuticals, Inc., a clinical-stage central nervous system (CNS) biopharmaceutical company, had a productive meeting with the Food and Drug Administration (FDA), who … Read more

Avail Scientific Signs Letter of Intent to Expand with Acquisition of Florida-Based Relai Neuro Neurological Testing Company

January 19, 2023 by Allen Williams

AVAIL SCIENTIFIC is thrilled to announce that it is taking an exciting step forward by entering into a letter of intent (LOI) to acquire Relai … Read more

Teva’s Bold Climate Goals Confirmed: SBTi Validates Ambitious Targets

January 19, 2023 by Allen Williams

Teva Pharmaceuticals Industries Ltd is proud to have its targets to reduce greenhouse gas (GHG) emissions approved by the Science Based Targets initiative (SBTi), demonstrating … Read more

Repare Therapeutics Reaps Record ¥200 Million Payment from Ono Pharmaceuticals

January 19, 2023 by Allen Williams

Repare Therapeutics Inc., a cutting-edge clinical-stage precision oncology company, announced that it has received a research service payment of approximately $1.5 million (¥200 million) from … Read more

Normunity Strengthens Leadership Team with Appointment of Olga Granaturova as COO and CBO

January 19, 2023 by Allen Williams

Normunity, Inc., a biotechnology company creating innovative precision anti-cancer immunotherapies, is thrilled to announce the appointment of Olga Granaturova, MBA, as Chief Operating Officer and … Read more

Surmodics’ SurVeil™ Drug-Coated Balloon Receives Major Regulatory Boost from the FDA

January 19, 2023 by Allen Williams

SurModics, Inc. announced that they have received a letter from the U.S. Food and Drug Administration (FDA) regarding their premarket approval (PMA) application for the … Read more

bluebird bio, Inc. Launches $120 Million Stock Offering: Time to Invest?

January 19, 2023 by Allen Williams

bluebird bio, Inc. announced the pricing of its public offering of 20,000,000 shares of common stock at a public offering price of $6.00 per share, … Read more

Kaneka Strengthens mRNA Production with Expansion of GMP Manufacturing Capacity at Eurogentec S.A.

January 19, 2023 by Allen Williams

Kaneka Corporation is taking the initiative to expand its GMP manufacturing capacity for mRNA with a capital investment of 2 billion JPY. By the end … Read more

Addex Shines Light on Corporate Progress and Financial Outlook

January 19, 2023 by Allen Williams

Addex Therapeutics Ltd, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a comprehensive corporate update from its headquarters in Geneva, … Read more

Junshi’s Revolutionary PD-1 Blocker Gives Hope to NSCLC Sufferers

January 19, 2023January 19, 2023 by Allen Williams

Junshi Biosciences announced Wednesday that their Phase III Neotorch trial of the anti-PD-1 monoclonal antibody, toripalimab, had achieved its primary endpoint in non-small cell lung … Read more

Novavax’s Nuvaxovid: South Korea Gives the Green Light to COVID-19 Booster Vaccine

January 19, 2023 by Allen Williams

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, is proud to announce that its partner SK bioscience has received … Read more

BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List

January 19, 2023 by Allen Williams

BeiGene is making history by expanding access to life-changing drugs in China! For the first time ever, drugs are being added to the nation’s Reimbursement … Read more

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

January 18, 2023 by Allen Williams

BriaCell Therapeutics Corporation is delighted to announce that its lead clinical candidate, Bria-IMT™, in combination with a checkpoint inhibitor, has been met with agreement and … Read more

Lupus Research Alliance Welcomes New Executive VP of Lupus Therapeutics: A Step Forward in the Battle Against Lupus

January 18, 2023 by Allen Williams

The Lupus Research Alliance (LRA) is delighted to announce the appointment of Stacie J. Bell, PhD as Executive Vice President to head up Lupus Therapeutics, … Read more

IceCure Unveils Revolutionary Cryogenic Pump for Next-Gen Cryoablation Systems, Receives Patent Allowance in Japan

January 18, 2023 by Allen Williams

Cryoablation technology is at the forefront of innovation, and we are proud to be a global leader in this field. Our success is evidenced by … Read more

FAP Therapeutic Targeting Achieves Major Success with SOFIE Partnership Grant

January 18, 2023 by Allen Williams

SOFIE Biosciences, a renowned US-based manufacturer of radiopharmaceuticals, is proud to announce its support of Yantai LNC Biotechnology’s recently FDA-approved clinical study – with the … Read more

First Patient Dosed in BOL-148 Clinical Trial: Ceruvia Lifesciences Paves the Way for New Hope in Medicine

January 18, 2023 by Allen Williams

Ceruvia Lifesciences made history today, dosing the first participant in their Phase 1 clinical trial of NYPRG-101 (2-bromo-d-lysergic acid diethylamide). The pioneering trial marks an … Read more

Edesa Biotech Announces Promising Phase 2b Results for Innovative Dermatology Drug

January 17, 2023 by Allen Williams

Researchers have been able to pinpoint the lowest effective dose of a medication or therapy, thanks to a successful study. This breakthrough provides an invaluable … Read more

Perimeter Medical Imaging AI Shakes Up Leadership with Appointment of Suzanne Foster as Board Chair

January 17, 2023 by Allen Williams

Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF, FSE: 4PC) – a commercial-stage medical technology company – is proud to announce its new Board … Read more

Unlock Cancer’s Secrets: TCT BioPharm Joins Forces to Harness the Power of Gamma Delta T Cells

January 17, 2023 by Allen Williams

Exploring the role of gamma-delta T cells in oncological settings is an exciting area of research with potentially groundbreaking implications. By devoting our attention to … Read more

Aclarion Welcomes George Frey MD as Latest KOL Surgeon Advisor: Advancing Innovative Solutions for Patients

January 17, 2023 by Allen Williams

Aclarion, Inc., a healthcare technology company utilizing biomarkers and proprietary augmented intelligence algorithms to help physicians determine the source of chronic low back pain, is … Read more

Biobeat Unveils Astounding Ability to Foresee Heart Failure Symptoms During Diuresis

January 17, 2023 by Allen Williams

A recent study published in the Journal of Clinical Medicine has validated the efficacy of Biobeat’s wrist monitor for advanced noninvasive hemodynamic monitoring in heart … Read more

Agilis RoboticsTM Succeeds in Pioneering Endoscopic Surgery with Miniaturized Robotic Instruments on Live Animals

January 17, 2023 by Allen Williams

Agilis RoboticsTM (Agilis) is revolutionizing endoscopic surgery with its groundbreaking robotic instruments. Co-founder Dr. Jason Y.K. Chan recently completed a successful live animal test on … Read more

New Results Show OncoK9 Liquid Biopsy Test Can Revolutionize Cancer Detection in Dogs

January 17, 2023 by Allen Williams

OncoK9’s potential for detecting cancer recurrence and residual disease after surgery or treatment is impressive, as evidenced by the results of PetDx’s analysis. With its … Read more

Ascletis Makes Major Move with Supply Agreement of Ritonavir Tablets and Simcere

January 17, 2023 by Allen Williams

Ascletis Pharma Inc. (HKEX: 1672), a China-based biopharmaceutical company, announced today that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply … Read more

Base Editing Could be a Breakthrough Treatment for Heart Disease

January 17, 2023 by Allen Williams

Scientists from the University of Texas Southwestern Medical Center have made a remarkable breakthrough: using base editing technology, they have managed to repair damaged heart … Read more

CER-001 Shines in Clinical Trial: Promising Treatment for Septic Patients at Risk of Acute Kidney Injury

January 17, 2023 by Allen Williams

We are delighted to report that our clinical trial has produced positive results on both primary and secondary endpoints, allowing us to identify a dose … Read more

China Approves Revolutionary Biosimilar to Actemra®, Providing Hope to Patients Everywhere

January 17, 2023 by Allen Williams

World’s First Approved Biosimilar to Actemra® Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company based in Guangzhou, China, has just made a major breakthrough in medical … Read more

CARsgen Therapeutics and Huadong Medicine Unveil Revolutionary Cancer Treatment: Zevorcabtagene Autoleucel Now Available in China

January 16, 2023 by Allen Williams

CARsgen Therapeutics Holdings Limited (2171.HK) and Huadong Medicine (Hangzhou) Co., Ltd., a subsidiary of Huadong Medicine Co., Ltd. (SZ: 000963), have joined forces in an … Read more

KAZIA Scores Major Funding Boost to Advance R&D Projects

January 16, 2023 by Allen Williams

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is delighted to announce a placement of KZA shares to institutional and sophisticated investors in Australia, at a … Read more

Groundbreaking Scientist in Computational Biology Joins Predictive Oncology’s Scientific Advisory Board

January 16, 2023 by Allen Williams

Predictive Oncology Inc. (NASDAQ: POAI) is thrilled to announce the appointment of Robert F. Murphy, Ph.D. to its Scientific Advisory Board. With his expertise and … Read more

Cytovance Biologics Welcomes Ping Zhang as New Chief Executive Officer

January 16, 2023 by Allen Williams

Cytovance Biologics, a premier biopharmaceutical CDMO of mammalian and microbial biologics, is proud to announce the appointment of Ping Zhang as its new Chief Executive … Read more

Silence Therapeutics Unveils Breakthrough Clinical Programs for SLN360 and SLN124

January 16, 2023 by Allen Williams

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a pioneering biotechnology company dedicated to improving lives by developing precision-engineered medicines to silence diseases, provided … Read more

Unlock the Power of Cell-Based Manufacturing with the New CliniPrime Suite from Charles River

January 16, 2023 by Allen Williams

Introducing CliniPrime Fresh Leukopak, the revolutionary technology that will revolutionize clinical trials and advance the commercialization of advanced therapies. With this launch, we are revolutionizing … Read more

Biolase Named ‘Top Workplace’ for 2022!

January 16, 2023 by Allen Williams

BIOLASE, Inc., the leading global provider of dental lasers, was recently honored with the prestigious Top Workplaces 2022 award from the Orange County Register. The … Read more

Extendicare to Reward Shareholders with C$0.04 Dividend in January 2023!

January 16, 2023 by Allen Williams

Extendicare Inc. (TSX: EXE) declared a cash dividend of C$0.04 per Common Share for the month of January 2023, to be paid out on February … Read more

A Potential Breakthrough: Eisai Submits Marketing Authorization Application for Innovative Treatment of Early Alzheimer’s Disease in Japan!

January 16, 2023 by Allen Williams

BioArctic AB’s partner, Eisai, has recently submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril[1] antibody for the treatment of mild … Read more

Sam Libby Joins EDP Biotech to Fuel Rapid Expansion Plans

January 16, 2023 by Allen Williams

EDP Biotech Corporation is thrilled to welcome Sam Libby as their new Head of Mergers & Acquisitions and Corporate Development. With Libby’s expertise on board, … Read more

IDEXX Partners with Volition to Offer Revolutionary Nu.Q® Vet Cancer Test to Veterinary Patients Everywhere

January 16, 2023January 16, 2023 by Allen Williams

VolitionRx Limited (NYSE AMERICAN: VNRX) is proud to announce the launch of its revolutionary Nu.Q® Vet Cancer Test, now available in the United States through … Read more

ALiA BioTech’s Revolutionary Diagnostic Platform Revolutionizes Multiplex Testing for Medical Professionals

January 16, 2023 by Allen Williams

ALiA BioTech’s rapid diagnostic platform is capable of providing up to 30 accurate results from a single drop of body fluid – whether it be … Read more

Revolutionary Treatment for Early Alzheimer’s Disease in Japan: Eisai Submits Application for Lecanemab Marketing Authorization

January 16, 2023 by Allen Williams

Eisai Co., Ltd. and Biogen Inc. have made a groundbreaking announcement today: they have jointly submitted a marketing authorization application for lecanemab, a revolutionary anti-amyloid … Read more

Clover Aims to Make 2023 a Breakthrough Year with COVID-19 Vaccine Commercial Launch and Strategic Priorities

January 16, 2023 by Allen Williams

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197) has made a commitment to use innovative vaccines to save lives and improve public health across the world. Today, … Read more

First Step to Combatting COVID-19: 4 Healthy Subjects Begin Multiple-Dose Clinical Trial of Oral 3CLpro Inhibitor ASC11

January 16, 2023 by Allen Williams

Enrolling 72 healthy volunteers, we are excited to launch a multiple-dose escalation Phase I clinical trial in the first quarter of 2023. Be a part … Read more

Lilly Unveils ‘Extraordinary Year’ Ahead, Highlighting Promising Pipeline

January 12, 2023 by Allen Williams

Eli Lilly had an incredible year with the launch of their diabetes drug Mounjaro (tirzepatide). Now, the company is gearing up for an even bigger … Read more

Alto’s Groundbreaking Biomarker Test Shows Promising Results in Treating Depression

January 12, 2023 by Allen Williams

As JP Morgan week kicked off in 2023, Alto Neuroscience was named number seven on BioSpace’s NextGen Bio 2023 list and brought with it positive … Read more

AbbVie Braves Uncertainty with Humira, Asserts Unwavering Commitment to Long-Term Growth

January 12, 2023 by Allen Williams

At the 41st J.P. Morgan Healthcare Conference in San Francisco, AbbVie’s CEO Rick Gonzalez talked about the company’s plans to adjust to the impending loss … Read more

Midatech Pharma PLC Advances MTX-110 Phase 1 Study with Planned Dose Escalation

January 12, 2023 by Allen Williams

Midatech Pharma PLC is delighted to announce that their Phase I study of MTX-110 in recurrent glioblastoma (NCT 05324501) will continue with a planned dose … Read more

IRLAB Unveils Exciting New Drug Candidate IRL1117 from P003 Project to Combat Parkinson’s Disease!

January 12, 2023 by Allen Williams

IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a Gothenburg-based company developing pioneering treatments for Parkinson’s disease, has nominated a drug candidate from its P003 research … Read more

Revolutionary PRIMA Implant Restores Vision at 5X Higher Resolution: Groundbreaking Study Reveals Potential

January 12, 2023 by Allen Williams

Pixium Vision has achieved a major milestone — the publication of two peer-reviewed studies showcasing the potential of the Next Generation PRIMA implant to restore … Read more

Biophytis Braces for Action After Receiving Nasdaq Deficiency Notice

January 12, 2023 by Allen Williams

Biophytis SA (NasdaqCM: BPTS)(Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics to slow the degenerative processes of aging and … Read more

Breakthrough Trial Results: Oramed’s ORMD-0801 Proven to Significantly Improve Type 2 Diabetes Treatment!

January 12, 2023 by Allen Williams

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company dedicated to the development of oral drug delivery systems, has released the top-line results of its … Read more

iNtRON Completes Tech Transfer for Revolutionary SAL200 Technology

January 12, 2023 by Allen Williams

iNtRON Biotechnology is delighted to announce that their Tech Transfer process for SAL200, a revolutionary endolysin-based biologic, is entering its final stage! This out-licensing and … Read more

Mountain Valley MD Announces Chief Medical Officer Moving to Advisory Role: New Era Ahead

January 12, 2023 by Allen Williams

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a biotech business focused on the licensing and reselling of … Read more

FDA Clears MTD Group’s Groundbreaking Passive Safety Needle: Innovative Design for Safer Injections

January 11, 2023 by Allen Williams

MTD Group – a global leader in medical devices – is proud to announce that its affiliate Pikdare S.p.A. has just obtained FDA clearance for … Read more

S2 Genomics Partners with Bonsailab to Deliver Cutting-Edge Life Science Solutions to Iberian Peninsula

January 11, 2023 by Allen Williams

S2 Genomics, Inc., a leader in single-cell genomics and cell biology applications, is thrilled to announce its new distribution agreement with Bonsailab. This agreement enables … Read more

Axonics Sees Early 2022 Revenue Surge and Predicts Further Growth in 2023

January 11, 2023 by Allen Williams

Our total company net revenue is expected to skyrocket over the next two years! For Q4 of 2021, we forecast an impressive 61% y/y increase, … Read more

Unveiling the Future of Animal Health Care: Zomedica to Present at Sidoti Virtual Investor Conference

January 11, 2023 by Allen Williams

Zomedica Corp. (NYSE American:ZOM), a veterinary health company that provides point-of-care diagnostics and therapeutic products for companion animals, announced that CEO Larry Heaton will be … Read more

U.S. Trade Judge Finds Apple Guilty of Stealing Masimo’s Pulse Oximeter Technology

January 11, 2023 by Allen Williams

Apple has been found to be in violation of the Tariff Act of 1930, after a United States Administrative Law Judge in Washington, D.C. determined … Read more

Mirum Pharmaceuticals Grants Inducements to Achieve Nasdaq Listing Rule 5635(c)(4) Compliance – Jan 11, 2023

January 11, 2023 by Allen Williams

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) granted inducement awards to four new employees under its 2020 Inducement Plan on January 10, 2023. Each employee was offered … Read more

MediciNova Set to Secure Canadian Patent for Scleroderma and Systemic Sclerosis Treatments MN-001 and MN-002!

January 11, 2023 by Allen Williams

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), has … Read more

Eisai Submits Groundbreaking Application to EU for Lecanemab as Treatment for Early-Stage Alzheimer’s Disease

January 11, 2023 by Allen Williams

BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has made a major move in the fight against Alzheimer’s disease today, submitting a marketing authorization … Read more

10 February 2023: Don’t Miss Out on an Extraordinary Opportunity — Join Us for the Shareholders’ EGM at Sequana Medical!

January 11, 2023 by Allen Williams

Sequana Medical NV (Euronext Brussels: SEQUA), a leader in the treatment of fluid overload in liver disease, heart failure, and cancer, is cordially inviting all … Read more

Basilea Surpasses 2022 Revenue Guidance, Announces Portfolio Updates!

January 11, 2023 by Allen Williams

Fiscal year 2022 was a banner year for Basilea Pharmaceutica Ltd, with significant revenue contributions from the commercial success of Cresemba and Zevtera and proceeds … Read more

Santhera Makes Major Move: Closes CHF 5 Million Share Exchange Deal

January 10, 2023 by Allen Williams

Santhera Pharmaceuticals (SIX: SANN) is pleased to announce that, through a share exchange, it will receive the equivalent of CHF 5 million Idorsia shares. This … Read more

Revolutionary Ameluz-PDT Study Begins: First Patient Dosed in Phase 3 Clinical Trial for Actinic Keratosis Treatment!

January 10, 2023 by Allen Williams

Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced a major milestone in its development as the first patient … Read more

Unveiling the Promising Results of IGM-8444: IGM Biosciences Announces Updates on Phase 1 Trial and Future Clinical Development

January 10, 2023 by Allen Williams

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company dedicated to the development of IgM antibodies, today shared an update on its clinical development program … Read more

Novocure Reports Record-Breaking 2022 Revenues and Offers Company Update

January 10, 2023 by Allen Williams

NovoCure Ltd. (NASDAQ: NVCR), a global oncology company dedicated to extending survival for those suffering from some of the most aggressive forms of cancer, announced … Read more

76 Revio Systems Ordered in Fourth Quarter: Pacific Bio Sees Record Growth in 2022

January 10, 2023 by Allen Williams

PacBio is thrilled to announce the launch of their PacBio Compatible Program, accompanied by positive Onso Beta feedback and preliminary fourth quarter 2022 revenue figures. … Read more

PerkinElmer Set to Unveil Fourth Quarter Results on Tuesday: Get Ready for Big News!

January 10, 2023 by Allen Williams

PerkinElmer Inc., a leading innovator driving a healthier world, will announce its fourth quarter and full year 2022 financial results on Tuesday, February 14th, 2023 … Read more

Celltrion and Rani Therapeutics Unveil Revolutionary Oral Monoclonal Antibody Treatment

January 10, 2023 by Allen Williams

Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) – a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs – today announced an exciting … Read more

Unlocking Global Opportunities: SK Bio Night in San Francisco

January 10, 2023 by Allen Williams

SK Inc. is set to spark innovative ideas and identify new business opportunities with its global strategy and growth roadmap at an event attended by … Read more

Berkeley Lights Unveils Revolutionary Optofluidic System, Beacon Select™, to Streamline Cell Line Development

January 10, 2023 by Allen Williams

Introducing a revolutionary new optofluidic system – a two-chip, single-cell device perfect for small to mid-sized biopharma and CDMOs/CROs. Now, you can have access to … Read more

TRexBio and Lilly Forge Partnership to Create Next-Generation Treatments for Immune-Mediated Diseases

January 10, 2023 by Allen Williams

TRex Bio, Inc., a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, has announced a multi-year research collaboration and exclusive worldwide license … Read more

CONMED Corporation to Unveil Fourth Quarter 2022 Financial Results – February 2, 2023

January 10, 2023 by Allen Williams

CONMED Corporation (NYSE: CNMD) today announced that it will report its financial results for the fourth quarter of 2022 after market close on Thursday, February … Read more

Fazirsiran Shows Promising Results in Treating Liver Disease Associated with Alpha-1 Antitrypsin Deficiency: Arrowhead and Takeda’s SEQUOIA Phase 2 Study

January 10, 2023 by Allen Williams

Arrowhead Pharmaceuticals announced positive results from the Phase 3 clinical trial of fazirsiran for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Patients receiving fazirsiran experienced … Read more

Unlock New Insights Into Brain Health: Quanterix Launches Neurofilament Light Chain Test

January 10, 2023 by Allen Williams

Quanterix Corporation (NASDAQ: QTRX) is revolutionizing scientific discovery and breakthrough diagnostics through their ultrasensitive biomarker detection. Today, the company has announced the validation of a … Read more

Marinus Pharmaceuticals Award Inducement Grants to Further Nasdaq Listing Goals

January 10, 2023 by Allen Williams

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, recently granted inducement awards to two … Read more

Precision BioSciences: Reflection on Accomplishments and Vision for 2023 to Drive Portfolio Progress

January 10, 2023 by Allen Williams

Precision BioSciences, Inc. (Nasdaq: DTIL) is proud to announce its impressive accomplishments in 2022 and outline its plans for 2023. The clinical-stage gene editing company … Read more

Castle Biosciences Reports Impressive Growth in Q4 and Full-Year 2022

January 9, 2023 by Allen Williams

We are proud to report that our total revenue for 2022 is expected to exceed the top end of the guided range of $132–137 million. … Read more

Agios Set to Revolutionize Rare Disease Treatment: 2023-2026 Catalysts to Drive Improved Patient Outcomes

January 9, 2023 by Allen Williams

We are excited to announce five pivotal trials in the field of rare hematological diseases, with strong clinical data to support them. Our goal is … Read more

Final Phase 2 Clinical Results Reveal Promising 35% Response Rate for Genexine’s Cervical Cancer Program: Check Out the Corporate Overview at JP Morgan Conference

January 9, 2023 by Allen Williams

Genexine, a Korean biopharmaceutical company dedicated to discovering and developing treatments for unmet medical needs, has released new results from their Phase 2 clinical study … Read more

PBS Biotech Secures $22M Investment to Revolutionize Cell Therapy Manufacturing!

January 9, 2023January 9, 2023 by Allen Williams

PBS Biotech, a leader in single-use bioreactors and process development services, recently announced the completion of a $22 million financing round led by Avego Management, … Read more

Breakthrough Alzheimer’s Treatment LEQEMBI Receives FDA Approval for Traditional Use, Thanks to Eisai and BioArctic Partnership

January 9, 2023January 9, 2023 by Allen Williams

BioArctic AB’s partner Eisai announced today that they have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) in … Read more

ChromaDex Welcomes Brianna Gerber as New CFO to Lead Financial Strategy

January 6, 2023 by Allen Williams

ChromaDex Inc. (NASDAQ: CDXC), a leading bioscience company devoted to healthy aging, is delighted to announce the appointment of Brianna Gerber as its new Chief … Read more

IONIQ Sciences Set to Revolutionize Biotech at Upcoming Trade Show

January 9, 2023January 6, 2023 by Allen Williams

IONIQ Sciences, Inc., formerly known as ProLung, Inc., is excited to announce its attendance at Biotech Showcase™, the globally renowned investor conference for innovators. CEO … Read more

Athira Pharma: A Glimpse Into the Future – Unveiling their 2023 Pipeline Outlook!

January 6, 2023 by Allen Williams

We are thrilled to be advancing our small molecule therapeutic candidates, which have promising clinical and preclinical data suggesting neuroprotective, neurotrophic, procognitive, and disease-modifying effects. … Read more

Revolutionary HeartBeam Technology Granted Patent to Transform Vector ECG Signals into 12-Lead ECGs

January 9, 2023January 6, 2023 by Allen Williams

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, is … Read more

Kira to Make a Splash at the 41st Annual J.P. Morgan Healthcare Conference

January 6, 2023 by Allen Williams

Kira Pharmaceuticals, a biotechnology leader in cutting-edge complement therapies to treat immune-mediated diseases, is proud to announce that Frederick Beddingfield M.D., Ph.D., Chief Executive Officer, … Read more

Triumvira and Merck Join Forces to Explore Potential of Cell Therapy and KEYTRUDA® in HER2-positive Solid Tumors

January 6, 2023 by Allen Williams

Triumvira Immunologics, a clinical-stage company developing groundbreaking T cell therapies to fight solid tumors, today announced a clinical trial collaboration and supply agreement with Merck. … Read more

BioSpace Unveils Interactive Maps of the Hottest Biotech Hotspots

January 6, 2023 by Allen Williams

Looking for the biotech industry’s hottest spots? Look no further than BioSpace’s exclusive Hotbed Maps! Our vibrant, one-of-a-kind map highlights the nine regions to watch … Read more

Moderna, Bayer Lead $275M Series B Funding for Metagenomi: Unlocking the Power of Microbes for a Healthier World

January 6, 2023 by Allen Williams

Metagenomi is starting the new year off with a bang, having just secured an additional $100 million in a Series B extension financing round announced … Read more

NovoCure Electrifies NSCLC Space with Pivotal Phase III Win

January 6, 2023 by Allen Williams

NovoCure Ltd., based in Switzerland, has just announced that its Phase III LUNAR trial has successfully met its primary endpoint in patients with non-small cell … Read more

Third Patient Fatality Prompts Urgent Calls for FDA Action Ahead of Lecanemab Decision

January 9, 2023January 6, 2023 by Allen Williams

As the FDA nears its decision on Biogen and Eisai’s lecanemab, a new potential death linked to the Alzheimer’s drug has been revealed in a … Read more

Aramchol: A Promising New Treatment for NASH, According to Galmed’s Phase III Data

January 9, 2023January 5, 2023 by Allen Williams

Galmed Pharmaceuticals’ synthetic small molecule candidate, aramchol, has proven to be a powerful tool in the fight against non-alcoholic steatohepatitis (NASH), following Phase III ARMOR … Read more

Emergent Reports Explosive Revenue Growth of Over 100% for Quarter Ended December 31st, 2022

January 9, 2023January 5, 2023 by Allen Williams

Emergent Health Corp. (OTC PINK:EMGE), a leading provider of innovative products in the Regenerative Health Space, has reported an impressive 100% quarter-over-quarter revenue increase for … Read more

Psilocybin-Assisted Psychotherapy: Tryp Therapeutics Sees Promising Interim Results in Phase II Clinical Trial for Binge Eating Disorder!

January 9, 2023January 5, 2023 by Allen Williams

Psilocybin-assisted psychotherapy appears to be a promising treatment approach for Binge Eating Disorder, with preliminary research showing encouraging results. By combining the power of psychedelic-assisted … Read more

Duality Biologics Unlocks the Future of Cancer Treatment with License Agreement for Next-gen ADC Platform with Adcendo

January 5, 2023 by Allen Williams

Duality is thrilled to announce the granting of a license for its DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP … Read more

Unlock the Potential of Ascentage Pharma at the 41st Annual J.P. Morgan Healthcare Conference!

January 9, 2023January 5, 2023 by Allen Williams

Ascentage Pharma (6855.HK), a pioneering biopharmaceutical company revolutionizing the way cancer, chronic hepatitis B (CHB), and age-related diseases are treated, is thrilled to announce that … Read more

Discover How YDS Pharmatech is Revolutionizing Biotech at Biotech Showcase™ During J.P. Morgan Week 2023!

January 5, 2023 by Allen Williams

YDS Pharmatech, Inc., a techbio startup revolutionizing drug design with its low-data-dependent AI solutions, is proud to present its latest innovations at Biotech Showcase™ 2023. … Read more

InnoCare to Take Center Stage at 2023 ASCO GI with Latest Gunagratinib Clinical Data!

January 9, 2023January 5, 2023 by Allen Williams

InnoCare Pharma (HKEX: 09969; SSE: 688428), a pioneering biopharmaceutical company dedicated to the treatment of cancer and autoimmune diseases, is pleased to announce that it … Read more

WuXi Biologics and GSK Forge Groundbreaking License Agreement for Novel Multi-Specific T Cell Engagers

January 9, 2023January 5, 2023 by Allen Williams

WuXi Biologics has just signed an exclusive license agreement with GSK that grants them access to preclinical bi-specific T cell engaging (TCE) antibodies, with the … Read more

Biotech Execs Gather at JPMorgan for Groundbreaking 2023 Kickoff

January 9, 2023January 5, 2023 by Allen Williams

JPMorgan week is proving to be a successful return to the pre-pandemic days, with executives flocking to San Francisco after two years of COVID-19-enforced absence. … Read more

Revolutionary KRAS G12C Inhibitor Receives Breakthrough Therapy Designation from NMPA for Treating Advanced Non-small Cell Lung Cancer!

January 9, 2023January 5, 2023 by Allen Williams

Innovent Biologics, Inc. – a leading global biopharmaceutical company – has been granted Breakthrough Therapy Designation (BTD) by China’s National Medical Products Administration (NMPA) for … Read more

Virax Biolabs Unveils Revolutionary HPV Test Kit – A Breakthrough in Early Detection!

January 9, 2023January 4, 2023 by Allen Williams

Virax Biolabs, a cutting-edge biotechnology firm dedicated to the prevention, detection, and diagnosis of viral diseases, has just announced the launch of its HPV test … Read more

Fresh Safety Concerns for Amgen’s Repatha Raises Alarm: Reanalysis of Key Trial Flags Troubling Results

January 9, 2023January 4, 2023 by Allen Williams

The FOURIER trial recently revealed that Amgen’s injectable cholesterol therapeutic, Repatha (evolocumab), may lead to an increased risk of cardiovascular death. This finding was revealed … Read more

Pharnext Builds a Stronger Leadership Team with the Appointment of Scott Johnson as VP of Quality

January 9, 2023January 4, 2023 by Allen Williams

Pharnext SA (FR001400BV89:ALPHA), an innovative biopharmaceutical company that is developing groundbreaking treatments for neurodegenerative disorders with an urgent need for solutions, is delighted to welcome … Read more

Life-Saving Oncopeptides Appoints Monica Shaw as New CEO, Jakob Lindberg as Chief Scientific Officer

January 9, 2023January 4, 2023 by Allen Williams

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company dedicated to advancing treatments for hard-to-treat hematologic diseases, has appointed Dr Monica Shaw as its new … Read more

CANbridge Sets Its Sights on Gene Therapy Leadership

January 9, 2023January 4, 2023 by Allen Williams

We are thrilled to announce that we have secured exclusive global rights to a potentially best-in-class gene therapy for Spinal Muscular Atrophy from UMass Chan … Read more

FDA Approval of Bioretec’s RemeOs™ Trauma Screws Expected in April 2023

January 9, 2023January 4, 2023 by Allen Williams

Bioretec Ltd, a leader in bioresorbable orthopedic implants, have received confirmation from the FDA that their supplement for the market authorization request for the RemeOs™ … Read more

Start Planning for 2022 Now: Model Your Future with the Q4 2022 Memorandum

January 9, 2023January 4, 2023 by Allen Williams

Sanofi proudly announced today that the Memorandum for Q4 2022, for modelling purposes, is now available for investors to access on the company’s website. This … Read more

Revolutionary Orano Med Alpha Radioligand Therapy 212Pb-GRPR Initiates First Human Clinical Trial in Fight Against Solid Tumors

January 4, 2023 by Allen Williams

Orano Med, a pioneering clinical stage radiopharmaceutical company, today announced a major breakthrough with the first patient being dosed in their Phase 1 trial of … Read more

Hemogenyx Pharmaceuticals PLC Achieves Milestone with Successful Completion of HEMO-CAR-T Process Qualification Run

January 9, 2023January 4, 2023 by Allen Williams

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is thrilled to report the successful accomplishment of its second Process Qualification (“PQ”) run of the end-to-end manufacturing process for its … Read more

Sedana Medical Achieves U.S. FDA Fast Track Status: A Major Step Towards Improved Health Care Access

January 9, 2023January 4, 2023 by Allen Williams

Sedana Medical AB (publ) (SEDANA: FN Stockholm) is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) … Read more

TherapeuticsMD Announces Major Breakthrough: Licensing Products to Mayne Pharma

January 9, 2023January 3, 2023 by Allen Williams

TherapeuticsMD, Inc. (NASDAQ: TXMD) has successfully completed the previously announced transaction with Mayne Pharma Group Limited, an ASX-listed specialty pharmaceutical company. Through this agreement, TherapeuticsMD … Read more

Apnimed Set to Shake up Sleep Apnea Treatment Market with AD109: $79.75M Series C Extension to Fund Phase 3 Trials

January 9, 2023January 3, 2023 by Allen Williams

Phase 3 Trials for a potential new treatment are set to begin enrollment in the second quarter of 2023, pending discussions with the FDA. Exciting … Read more

ResMed Ready to Make Waves at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023 by Allen Williams

ResMed (NYSE: RMD, ASX: RMD) is pleased to announce that Mick Farrell, its chief executive officer, will take the stage at the 41st Annual J.P. … Read more

Blacksmith Medicines Forges Innovative Partnership with Forge Therapeutics to Create Revolutionary Medicines Targeting Metalloenzymes

January 9, 2023January 3, 2023 by Allen Williams

Blacksmith Medicines and Forge Therapeutics are joining forces to revolutionize the biopharma industry with a groundbreaking merger. Combining their chemistry platforms, the companies are dedicated … Read more

Unlock the Potential of B cells with argenx at the 41st Annual J.P. Morgan Healthcare Conference

January 9, 2023January 3, 2023 by Allen Williams

argenx, a global immunology company dedicated to transforming the lives of those living with severe autoimmune diseases, is proud to announce that its Chief Executive … Read more

Antengene Set to Make a Big Splash at the J.P. Morgan Healthcare Conference!

January 3, 2023 by Allen Williams

Antengene Corporation Limited (SEHK: 6996.HK) is thrilled to announce that it will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January … Read more

Blue Light Cystoscopy: Clinical Benefits Highlighted in New Study, Supporting Increased Reimbursement

January 3, 2023 by Allen Williams

Photocure ASA, The Bladder Cancer Company, is pleased to announce the publication of a groundbreaking study in Urologic Oncology this week. Entitled ‘Clinical and Economic … Read more

Revolutionary Study Tests Accuracy of Masimo SpHb® Noninvasive Hemoglobin Monitoring During Elective Cesarean Section

January 9, 2023January 3, 2023 by Allen Williams

Masimo SpHb has been shown to measure hemoglobin levels with “clinically acceptable accuracy” – even at the lowest levels. This breakthrough technology offers reliable and … Read more

Minovia Therapeutics to Showcase Innovative Therapies at J.P. Morgan Health Care Conference

January 9, 2023January 3, 2023 by Allen Williams

Minovia Therapeutics, a clinical-stage global biotechnology company, is thrilled to announce its attendance at the upcoming Biotech Showcase in San Francisco, CA on Tuesday, January … Read more

Sirona Biochem Celebrates Annual Meeting Success in 2022

January 9, 2023January 2, 2023 by Allen Williams

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) held its Annual General Meeting of Shareholders in Vancouver, British Columbia on December 30, 2022, with … Read more

MedMira Soars in Q1: Record-Breaking Results for FY2023

January 2, 2023 by Allen Williams

MedMira Inc. (TSXV:MIR) unveiled its financial results for the quarter ending October 31, 2022, revealing a period of strong growth and increased profitability. The Halifax-based … Read more

BeiGene’s Tislelizumab Receives 12th Regulatory Approval in China: A Step Closer to Cancer Treatment Breakthrough

January 2, 2023 by Allen Williams

The submission to regulatory authorities is a crucial step towards obtaining marketing authorization for the use of a new treatment in the fight against unresectable … Read more

Making History: OncoC4 Inaugurates First Patient in New Clinical Trial Combining ONC-392 and KEYTRUDA® for Platinum-Resistant Ovarian Cancer

January 2, 2023 by Allen Williams

Building on the promising results of its monotherapeutic activity in a previous clinical trial, ONC-392 is now entering Phase 2 of a multicenter, open-label combination … Read more

Harren Jhoti, Co-founder and CEO of Astex, Honoured with OBE in the King’s New Year Honours

January 9, 2023January 2, 2023 by Allen Williams

Astex Pharmaceuticals, UK, is proud to congratulate its co-founder, President and CEO, Harren Jhoti, PhD, FRS, FMedSci, on being honoured with an Officer of the … Read more

Canada Implements Negative COVID-19 Tests for Travellers from China, Hong Kong and Macao

January 2, 2023 by Allen Williams

“Two Years and Older: Negative COVID-19 Test Now Required for Air Travel to Canada!” In response to the surge of COVID-19 cases in the People’s … Read more

China Leads the Way in Adapting to Coronavirus Mutations for an Effective COVID-19 Response

January 9, 2023January 2, 2023 by Allen Williams

Experts have expressed their concerns that the loosening of China’s COVID-19 restrictions could lead to an increased risk of the virus mutating. William Schaffner, professor … Read more

Pfizer’s Gene Therapy for Hemophilia B Achieves Promising Results in Clinical Study!

January 9, 2023January 2, 2023 by Allen Williams

Pfizer Inc. (NYSE: PFE) announced today the positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) of its investigational gene therapy, fidanacogene elaparvovec, for … Read more

Overtime Granted: Evofem to File Quarterly Report on Form 10-Q for Q3 2022.

January 2, 2023 by Allen Williams

Evofem Biosciences, Inc. (OTCQB: EVFM) has been granted an extension by the OTC Markets Group to submit its Quarterly Report on Form 10-Q for the … Read more

Neuronetics Welcomes Joseph H. Capper to its Board of Directors with Open Arms!

January 2, 2023 by Allen Williams

With extensive experience in the industry, a new director has been appointed to position the company for growth. This individual brings an impressive knowledge base … Read more

Everest Medicines Unveils Exciting New Strategy: Join the Online Conference Calls!

January 9, 2023December 30, 2022 by Allen Williams

Everest Medicines (HKEX: 1952), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative medicines and vaccines, is proud to announce its new corporate strategy. … Read more

ABM Respiratory Care Announces the FDA Clearance of the BiWaze Clear System

December 30, 2022 by Allen Williams

ABM Respiratory Care, a leading medical technology company, is excited to announce the U.S. Food and Drug Administration’s 510(k) clearance of its groundbreaking BiWaze® Clear … Read more

Pharnext and Néovacs Join Forces for Next-Level Development

January 9, 2023December 30, 2022 by Allen Williams

Néovacs has made a significant commitment to increase its funding for the upcoming pivotal Phase III clinical trial of PXT3003, a potential treatment for Charcot-Marie-Tooth … Read more

NuGen Closes Initial Round of Investment, Raises Funds Through Unit Placement

December 30, 2022December 30, 2022 by Allen Williams

NuGen Medical Devices Inc. (TSXV:NGMD)(OTCQB:NGMDF) (“NuGen” or the “Company”) has successfully closed the first tranche of its non-brokered private placement, raising a total of $125,000 … Read more

Immix Biopharma Subsidiary Nexcella Presents Cutting-Edge Research at European CAR T-cell Meeting

January 9, 2023December 30, 2022 by Allen Williams

NXC-201, a pioneering CAR-T therapy for multiple myeloma and AL amyloidosis, will have its latest clinical data unveiled at the upcoming Rotterdam event on February … Read more

Nexcella Inc. Presents Breakthrough Poster at the European CAR T-Cell Meeting

January 9, 2023December 30, 2022 by Allen Williams

Come join us in Rotterdam, Netherlands February 9-11, 2023 for the presentation of updated clinical data on NXC-201, a next-generation CAR-T treatment for multiple myeloma … Read more

PDS Biotech Announces Dramatic Increase in Overall Survival for Advanced Cancer Patients With Few Treatment Options

December 30, 2022 by Allen Williams

The National Cancer Institute recently conducted a Phase 2 clinical trial to assess the efficacy of PDS0101 triple combination in treating HPV16-positive cancer patients who … Read more

Unlock New Opportunities: Varex to Showcase at CJS Securities 23rd Annual New Ideas for the New Year Virtual Investor Conference

January 9, 2023December 30, 2022 by Allen Williams

Varex Imaging Corporation (Nasdaq: VREX) is thrilled to announce its participation in CJS Securities 23rd Annual New Ideas for the New Year virtual investor conferences, … Read more

CEL-SCI Posts Impressive Financial Results and Advances Clinical & Corporate Developments for 2022

January 9, 2023December 30, 2022 by Allen Williams

CEL-SCI Corporation (NYSE American: CVM) recently announced its financial results for the fiscal year ended September 30, 2022, along with several noteworthy clinical and corporate … Read more

Revolutionary XENOVIEW™ Technology Now Available for MRI Evaluation of Lung Ventilation, Thanks to Polarean’s FDA Approval

January 9, 2023December 30, 2022 by Allen Williams

XENOVIEW is a groundbreaking hyperpolarized MRI contrast agent that is the first and only of its kind to receive FDA approval for both adolescents and … Read more

ATEC Showing Up and Showing Out at January 2023 Investor Conference!

January 9, 2023December 29, 2022 by Allen Williams

Alphatec Holdings, Inc. (Nasdaq: ATEC) is excited to announce its virtual participation in the 25th Annual Needham Growth Conference! Join us on January 12, 2023 … Read more

Stryker to Unveil What’s Next at Upcoming Conference Call on January 31, 2023

January 9, 2023December 29, 2022 by Allen Williams

Stryker (NYSE: SYK) has announced an upcoming conference call to review the company’s performance for the quarter ending December 31, 2022, and provide an operational … Read more

Akoya to Take Center Stage at J.P. Morgan Healthcare Conference

January 9, 2023December 29, 2022 by Allen Williams

Akoya Biosciences, Inc. (Nasdaq: AKYA) – The Spatial Biology Company® – is thrilled to announce that it will be taking part in the 41st Annual … Read more

High-Risk Adults Reap the Benefits of Junshi Biosciences’ VV116: Phase 3 Study Results Published in NEJM

January 9, 2023December 29, 2022 by Allen Williams

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) is proud to announce that their Phase 3 trial (NCT05341609) comparing the efficacy and … Read more

Qilu Pharmaceuticals Unveils Breakthrough Clinical Results for Innovative Bifunctional Antibody QL1706

January 9, 2023December 29, 2022 by Allen Williams

Qilu Pharmaceutical is making waves in the medical industry with its innovative bifunctional antibody, QL1706, by presenting the latest progress of its clinical studies at … Read more

Skanska Constructs USD 111M Medical Education Facility for The University of Texas at Tyler – A SEK 1.1B Investment in Tyler, Texas

December 29, 2022 by Allen Williams

Skanska and HGR General Contractors have teamed up to construct a state-of-the-art medical education building for The University of Texas at Tyler. The contract, worth … Read more

Skanska Invests Heavily to Expand San Antonio Hospital with $95M USD Project

January 9, 2023December 29, 2022 by Allen Williams

Skanska has secured a USD 95M (SEK 960M) contract to expand the Christus Santa Rosa Hospital-Westover Hills Hospital in San Antonio, Texas, USA. The project … Read more

Guardant Health’s Groundbreaking Medical Tech at J.P. Morgan Healthcare Conference!

December 29, 2022 by Allen Williams

Guardant Health, Inc. (Nasdaq: GH), a cutting-edge precision oncology company, is pleased to announce its attendance at the upcoming 41st Annual J.P. Morgan Healthcare Conference. … Read more

RxSight Inc. to Illuminate the J.P. Morgan Healthcare Conference 2023

January 9, 2023December 29, 2022 by Allen Williams

RxSight Inc., a leading ophthalmic medical device company committed to restoring the vision of cataract surgery patients, is thrilled to announce its participation in the … Read more

Houston Concierge Medicine Revolutionizes Executive Health Program with Cardio Diagnostics’ Innovative Epi+Gen CHD Test

December 29, 2022 by Allen Williams

Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) and Houston Concierge Medicine have joined forces to provide a revolutionary new test for coronary heart disease. Cardio Diagnostics’ … Read more

FDA Fast-Tracks Harm Reduction Therapeutics’ RiVive™ Over-the-Counter Naloxone Nasal Spray for Approval

December 29, 2022December 27, 2022 by Allen Williams

Harm Reduction Therapeutics (HRT), Inc., the 501(c)(3) nonprofit pharmaceutical company working to prevent opioid overdose deaths, has made an exciting breakthrough: the FDA has accepted … Read more

©2023